Constellation pharmaceuticals inc (CNST)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Revenue

-

-

-

-

-

-

-

-

-

0

0

-

0

Revenue

-

-

-

-

-

-

-

-

-

-

-

0

-

Operating expenses:
Research and development

20,075

18,586

16,241

15,955

15,677

16,626

12,733

9,536

9,874

-

7,690

8,022

-

General and administrative

5,908

5,471

4,810

4,886

4,429

4,006

3,680

2,486

2,303

-

1,981

1,490

-

Total operating expenses

25,983

24,057

21,051

20,841

20,106

20,632

16,413

12,022

12,177

11,888

9,671

9,512

8,017

Loss from operations

-25,983

-24,057

-21,051

-20,841

-20,106

-20,632

-16,413

-12,022

-12,177

-

-9,671

-9,512

-

Other income (expense):
Interest income

1,404

730

507

652

755

688

482

268

109

-

45

32

-

Interest expense

850

857

605

578

75

0

7

187

34

-

246

255

-

Change in fair value of preferred stock tranche liability

-

-

-

-

-

-

-

-

-

-

90

1,743

-

Total other income (expense), net

554

-127

-98

74

680

688

475

81

75

-44

-111

1,520

2,346

Loss before income taxes

-25,429

-

-

-

-19,426

-

-

-

-

-

-

-

-

Income tax expense

15

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-25,444

-

-

-

-19,426

-

-

-

-

-11,932

-9,782

-7,992

-5,671

Net loss per share attributable to common stockholders, basic and diluted

-0.61

-0.67

-0.82

-0.80

-0.75

18.21

-0.81

-9.96

-12.44

-17.64

-15.18

-12.81

-10.41

Weighted average number of common shares used in net loss per share attributable to common stockholders, basic and diluted

41,765

35,163

25,829

25,809

25,804

26,145

19,619

1,199

972

-

961

961

-

Comprehensive loss:
Net Loss

-25,444

-

-

-

-19,426

-

-

-

-

-

-

-

-

Cumulative dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

5,048

4,818

4,327

4,197

Other comprehensive gain (loss):
Unrealized gain (loss) on marketable securities

-84

-7

-10

2

9

-

-

-

-

-

-

-

-

Total other comprehensive gain (loss):

-84

-

-

-

9

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-21,149

-20,767

-

-19,944

-15,938

-11,941

-12,102

-16,980

-14,600

-12,319

-9,868

Total other comprehensive gain (loss):

-

-

-10

2

-

-

-

-

-

-

-

-

-

Comprehensive loss

-25,528

-

-21,159

-20,765

-19,417

-

-15,938

-11,941

-12,102

-

-

-

-